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Abstract  
Background: 
Sequence specific polyamide HxIP 1, targeted to the inverted CCAAT Box 2 (ICB2) on the 
topoisomerase II (topo II promoter can inhibit NF-Y binding, re-induce gene expression and 
increase sensitivity to etoposide. To enhance biological activity, diamino-containing derivatives 
(HxI*P 2 and HxIP* 3) were synthesised incorporating an alkyl amino group at the N1-
heterocyclic position of the imidazole/pyrrole. 
 
Methods: 
DNase I footprinting was used to evaluate DNA binding of the diamino Hx-polyamides, and their 
ability to disrupt the NF-Y:ICB2 interaction assessed using EMSAs. Topo II mRNA (RT-PCR) 
and protein (Immunoblotting) levels were measured following 18h polyamide treatment of 
confluent A549 cells. H2AX was used as a marker for etoposide-induced DNA damage after 
pre-treatment with HxIP* 3 and cell viability was measured using Cell-Titer Glo. 
 
Results: 
Introduction of the N1-alkyl amino group reduced selectivity for the target sequence 5’-
TACGAT-3’ on the topo II promoter, but increased DNA binding affinity. Confocal microscopy 
revealed both fluorescent diamino polyamides localised in the nucleus, yet HxI*P 2 was unable 
to disrupt the NF-Y:ICB2 interaction and showed no effect against the downregulation of topo 
II. In contrast, inhibition of NF-Y binding by HxIP* 3 stimulated dose-dependent (0.1-2 M) re-
induction of topo II and potentiated cytotoxicity of topo II poisons by enhancing DNA damage.  
 
Conclusions: 
Polyamide functionalisation at the N1-position offers a design strategy to improve drug-like 
properties. Dicationic HxIP* 3 increased topo II expression and chemosensitivity to topo II-
targeting agents.  
 
General Significance: 
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Pharmacological modulation of topo II expression has the potential to enhance cellular 
sensitivity to clinically-used anticancer therapeutics. 
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1. Introduction 
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Gene expression is precisely regulated by the binding of the transcription machinery to specific 
DNA sequences. Dysregulation of transcriptional activity leading to aberrant gene expression 
is a fundamental driver of a diverse array of human diseases. Sequence selective (P) Pyrrole - 
(I) Imidazole polyamides are able to modulate gene expression through binding non-covalently 
to specific DNA sequences and disrupting the DNA interactions of transcription factors. These 
reversible DNA minor groove binders can arrange in a stacked, antiparallel 2:1 (ligand:DNA) 
orientation and afford programmable sequence recognition, governed by the side-by-side 
heterocyclic ring pairing rules [1], [2], [3], [4]. A P/P pairing degenerately targets AT or TA, 
whereas P/I recognises CG and I/P preferentially binds to GC. The reported anti-cancer 
biological activity of these cell permeable small molecules in both cellular and in vivo studies 
has highlighted the potential of therapeutic strategies that directly target transcription factor-
DNA interfaces known to be implicated in certain malignant phenotypes [5], [6], [7], [8]. 
 
Nuclear Factor Y (NF-Y) is a heterotrimeric CCAAT-binding transcription factor involved in cell 
differentiation, proliferation and implicated in cancer progression [9], [10], [11], [12], [13]. NF-Y 
has been shown to bind to the promoter of the essential DNA processing enzyme, 
topoisomerase II  (topo II) and regulates its transcription through interactions with the 
inverted CCAAT box (ICB) sequences located within the promoter [14], [15], [16]. Topo II plays 
a critical role in DNA metabolism, maintaining genomic stability [17], and is the target of  
clinically-used chemotherapeutic agents etoposide and doxorubicin [18], with low levels of topo 
II conferring cellular resistance to these anticancer agents [19], [20], [21], [22]. NF-Y acts as 
both an activator and repressor of topo II transcription with increased association of NF-Y to 
the promoter exerting a negative effect at confluence [15], [16]. The ICB2 has been identified 
as the crucial DNA regulatory element and its interaction with NF-Y (Figure 1) mediates the 
confluence-induced downregulation of topo II and reduced chemosensitivity to topo II targeting 
therapeutics. 
Chemical approaches that re-induce topo II expression have the potential to increase cellular 
sensitivity to topo II poisons and to this end, our group has used various DNA binding small 
molecules and polyamides to inhibit the repressive activity of NF-Y on the topo II promoter 
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[16], [23], [24], [25], [26], [27].  Most recently, we reported the synthesis and biological activity 
of a novel polyamide incorporating the p-anisylbenzimidazole (Hx) DNA recognition element 
[28], [29]. Designed to enhance polyamide-DNA binding and cellular uptake, the Hx moiety 
exhibits intrinsic fluorescence upon binding DNA enabling the direct visualisation of polyamide 
nuclear localisation. Hx-polyamide HxIP (1, Figure 2A) designed to target the 5’-flanking 
sequence 5’-TACGAT-3’ of the ICB2 (Figure 1), binds to DNA with high affinity and sequence 
selectivity, and disrupts the NF-Y:ICB2 interaction resulting in the upregulation of topo II 
expression at confluence. HxIP pre-treatment enhanced etoposide-induced DNA damage, 
providing further evidence that sequence specific polyamides can re-sensitise confluence-
arrested cancer cells to topo II poisons [28]. 
 
The development of HxIP provides a new framework for the design of fluorescent sequence 
selective DNA binding molecules, distinct in configuration from the prototypical hairpin 
polyamide, yet capable of efficient nuclear localisation and in vitro gene regulation. In parallel, 
we have continued to explore an alternative strategy for further optimisation of polyamide 
physicochemical and DNA binding properties, through the introduction of an additional alkyl 
amino group at the N1 position of the heterocyclic rings [30], [31], [32], [33]. DNA binding studies 
by our groups revealed the small diamino polyamide containing an orthogonal positioned propyl 
amino group, f-IP*I (*denotes modified heterocycle) to have greater binding affinity than its 
monoamino counterpart and analogous sequence selectivity. Importantly, the inclusion of an 
extra amino group, which is cationic at physiological pH, also increases water solubility and 
may afford greater polyamide nuclear uptake. We aim to exploit this potential combination of 
improved DNA binding and solubility properties to engineer a potentially more potent generation 
of dicationic polyamides. 
 
This study presents the DNA binding and biological activities of the diamino Hx-polyamides 
HxI*P 2 and HxIP* 3, which incorporate the N1-alkyl amino group modification (Figure 2A). 
Polyamides 2 and 3 are functionalised derivatives of HxIP 1 and like their monoamino 
predecessor are designed to target the ICB2 5’-flanking sequence 5’-TACGAT-3’ on the topo 
II promoter (Fig 2B) and disrupt NF-Y binding, inducing topo II expression at confluence. 
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Comparison with the monoamino HxIP 1 will reveal the effect the inclusion of an N1-alkyl amino 
group in the Hx-framework has on DNA binding and the feasibility of using functionalization of 
the N1 position to enhance polyamide cellular uptake and biological activity. Additionally, we 
shall assess the potential chemosensitising effects of the diamino generation of polyamide 
inhibitors of NF-Y:DNA binding and the effectiveness of pharmacological modulation of topo II 
expression as a strategy for overcoming the drug resistance exhibited by confluence-arrested 
cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Methods and Materials  
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2.1 Synthesis of polyamides 
 
Details of the synthesis and characterisation of diamino Hx-polyamides 2 and 3 are provided in 
the supplemental materials and methods (Scheme S1). 
 
2.2 Thermal denaturation studies 
 
Thermal denaturation (ΔTM) studies were performed using a Cary Bio 100 spectrophotometer 
UV-Vis instrument (Palo Alto, CA) as previously described by Chavda et al [29]. DNA oligomers 
were purchased from Operon and the sequences are provided in the supplemental materials. 
Experiments for diamino Hx-polyamides 2 and 3 were performed at a concentration of 3 μM 
ligand and 1 μM DNA. All melts were performed in 10-mm path length quartz cells. TM values 
were determined as the maximum of the first derivative, and TM values are the difference 
between the melting temperatures of ligand bound DNA and free DNA. 
 
2.3 Circular dichroism  
 
Circular dichroism (CD) studies were carried out as previously reported [30], using an OLIS 
(Bogart, GA) DSM20 spectropolarimeter. Experiments were conducted at ambient temperature 
in a 1-mm path length quartz cell using phosphate a PO40 buffer (10 mM sodium phosphate, 1 
mM EDTA, pH 6.2). Buffer and stock DNA were added to the cuvette to give a final DNA 
concentration of 9 μM. Each diamino Hx-polyamide (in 500 μL in ddH2O) was titrated in 
increments of 1 molar equivalent into the relevant DNA (160 μL of 9 μM DNA). Each run was 
performed over 400–220 nm. The CD response at the λmax of the induced peak was plotted 
against the mole ratio of ligand to DNA. 
 
2.4 Surface plasmon resonance (SPR) 
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Surface plasmon resonance (SPR) measurements were performed with a four-channel BIAcore 
T100 optical biosensor system (Biacore, GE Healthcare Inc.). A streptavidin-coated sensor chip 
was prepared by a series injections of 1 M NaCl in 50 mM NaOH for periods of 60 s followed 
by washing of the chip surface with HBS buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 
0.05% P20, pH 7.4). Biotin-5’-end labelled DNA hairpin oligomers dissolved to 25 nM 
concentrations in HBS buffer were immobilized to the flow cell surface via non-covalent capture 
using previously described methods [34], [35]. The sequences of the three hairpin oligomers 
are detailed in the supplemental materials.  Three flow cells were used to immobilise the DNA, 
while a fourth was left blank as a control. Immobilization was achieved by manual injection of 
the DNAs at a flow rate of 1 µL/min until response units (RU) of 350-400 were reached. Diamino 
polyamide 3 was dissolved in 500 µL MeOH and 0.9 mol eq. of HCl was added to form a salt. 
Methanol was removed using N2 at 25 °C leaving a yellow salt. The compound was then re-
dissolved in ddH2O to a concentration near 1 mM and spectroscopically determined by UV-Vis 
using the extinction coefficient (ε322nm = 29,129 L∙mol-1∙cm-1) and stored at 4 °C until use (within 
2 weeks). Compound solution concentrations of 3 were prepared in 10 mM cacodylic acid 
(CCL), 1 mM EDTA, and 200 mM NaCl buffer (pH 6.5) ranging 2 nM - 1 µM and were injected 
over the sensor chip at a flow rate of 100 µL/min for 180 s. Buffer was then flowed over the chip 
surface for 600 s to dissociate bound HxIP* 3 from DNA. Following each cycle, the surface of 
the sensor chip was regenerated with 1 M NaCl for 30 s and rinsed with three injections of 
experimental buffer to produce a stable baseline for the following cycles. The relative response 
units (RU) were plotted as a function of free compound concentration (Cf) and equilibrium 
binding constants (Keq) were determined using a two-site cooperative binding model with the 
following equation: 
r = 
𝑅𝑈
𝑅𝑈𝑚𝑎𝑥
 = (K1·Cf + 2 K1·K2·Cf2)/(1 + K1·Cf + K1·K2·Cf2)   (1) 
Here, K1 and K2 are macroscopic binding constants in units per concentration (M-1). The 
maximum obtainable response (RUmax) in equation (1) was calculated from the product of 
immobilized DNA response units, HxIP* molecular weight, refractive index of HxIP*, and the 
inverse DNA molecular weight. The obtained maximum value was compared to predict RUmax 
of bound HxIP* to determine the stoichiometry. Equilibrium binding constants (Keq) were 
determined using both global kinetics fits and/or steady-state binding models. Two equilibrium 
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binding constants, K1 and K2, were determined, multiplied by each other, and the square root 
of the resulting calculated value gave an averaged equilibrium binding constant (Keq) to 
compare with previous results [29]. 
Keq = (K1·K2)1/2        (2) 
 
2.5 DNase I footprinting  
 
The 5’ radiolabelled DNA substrate corresponding to the topo II promoter was prepared by 
PCR amplification and then isolated and purified as previously reported [16]. The DNase I 
footprinting reactions were performed as described by Kiakos et al [28] and resolved on a 10% 
denaturing polyacrylamide-urea gel (National Diagnostics) by electrophoresis for 3 h at 1650 V 
(55C) in 1x TBE buffer. The gel was then transferred onto Whatman 3MM paper, dried and 
exposed overnight to Fuji medical X-ray film to visualise the radioactive signal. 
 
2.6 Cell lines and culture conditions 
 
NIH3T3 mouse fibroblast cells were obtained from CR-UK London Research Institute, and the 
A549 cell line was purchased from the European Collection of Cell Cultures. All cell lines were 
maintained in DMEM (Sigma-Aldrich) supplemented with 2mM L-glutamine (Sigma-Aldrich) and 
10% fetal bovine serum (Gibco, Life Technologies). 
 
2.7 Electrophoretic mobility shift assay (EMSA) 
 
Electrophoretic mobility shift assay (EMSA) experiments were conducted as outlined by Kiakos 
et al [28] using nuclear protein extracts from NIH3T3 fibroblast cells and the ICB2-containing 
oligonucleotide; 5’-GGCAAGCTACGATTGGTTCTTCTGGACG-3’ (sense); 5’-
CGTCCAGAAGAACCAATCGTAGCTTGCC-3’ (antisense). Oligonucleotides containing a 
mutated ICB2 were used as specific competitors, with the wild-type ICB motif replaced by 
AAACC and GGTTT in sense and antisense oligonucleotides respectively. For supershift 
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experiments the nuclear extract and radiolabelled oligonucleotide were incubated with anti-NF-
YA antibody (Abcam) for 1h. 
 
2.8 Immunofluorescence staining and confocal microscopy 
 
To assess polyamide nuclear uptake, A549 and NIH3T3 cells grown on 13-mm glass cover 
slips were treated with different concentrations of polyamide 2 and 3 for various incubation 
times. Cells were fixed (2% PFA), washed with PBS and then permeabilised to allow nuclear 
DNA staining with PI (2 g/ml). Alternatively, MitoTracker Red was used to stain the 
mitochondria, without fixation or permabilisation. The blue fluorescence of the Hx-polyamides 
was excited with a UV-laser (364 nm) and detected using the DAPI filter. PI/ MitoTracker Red 
was excited with an argon-ion laser (488 nm) and detected at 642 nm. The fluorescence of the 
polyamide was detected and imaged by z-stack acquisition using the Zeiss 510 UV-VIS 
microscope and the LSM510 software. Immunofluorescence was used to assay for H2AX foci 
induction after polyamide-etoposide combination treatment. A549 cells were washed with PBS, 
fixed with 2% PFA and permeabilised with PBS containing 0.5% Triton X-100. Cells were 
subsequently blocked in PBS 5% BSA for 1 h and incubated with anti-phospho-Histone H2A.X 
mouse monoclonal antibody (1:100; Millipore) diluted in PBS 1% BSA for 1h. After three 
washes, cells were incubated with the goat anti-mouse secondary antibody Alexa Fluor 488 
(1:100; Life Technologies) for another hour. Following a further three washes in PBS 0.1% 
Triton X-100, nuclei were stained using a PI solution (2 g/ml; Sigma-Aldrich). H2AX levels 
were then visualised using confocal microscopy and the number of foci per nuclei was 
quantified using the CellProfiler software [36], [37].  
 
 
2.9 Quantitative real time PCR 
 
RNA was isolated using the RNeasy Plus Mini Kit (Qiagen) and cDNA was generated with the 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Real time PCR was 
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carried out using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems) and 
Taqman assay probes (Life Technologies) for the target gene, topo II  (Hs01032137_m1) and 
the internal control, GAPDH (Hs03929097_g1). The relative quantification of topo II mRNA 
levels from untreated and polyamide treated confluent A549 cells was determined using the 
2^(-Ct) method and normalised to the internal control.  
 
2.10 Immunoblotting 
 
Nuclear extracts from A549 cell lines were prepared using a Nuclear Extraction Kit (Active Motif) 
following the manufacturer’s protocol. Protein concentration was quantified using the Bio-Rad 
DC protein assay. Nuclear proteins were separated on a NuPAGE 7% Tris-acetate gel (Life 
Technologies), transferred to PVDF membranes and blocked (5% w/v non-fat dry milk in 1x 
TBS, 0.1% Tween-20) for 1 h at ambient temperature. Topo II was identified by overnight 
incubation with topo II rabbit polyclonal antibody (1:5000, kindly provided by Dr I.D. Hickson, 
Weatherall Institute of Molecular Medicine, Oxford, UK) and subsequent incubation for 1 h with 
anti-rabbit secondary antibody. Chemiluminescent visualisation was performed using ECL 
reagent (Amersham) and exposure onto autoradiography film (Kodak-X-Omat). Protein levels 
of H2AX were also assessed after polyamide-etoposide combination treatment. For the 
detection of phosphorylated histone H2AX (Ser139), proteins were separated using a NuPAGE 
4-12% Bis-tris gel and probed using the anti-phospho-histone H2AX monoclonal antibody 
(1:500, Millipore). Lamin (Cell Signalling) was used as a loading control for the nuclear protein 
extracts. 
 
 
2.11 Cell viability  
 
The Cell Titer-Glo luminescent assay (Promega) was used as per manufacturer’s instructions 
to assess viability of A549 cancer cells after combination treatment with polyamide 3 and 
etoposide (400 M) or doxorubicin (75 M). 
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2.12 Statistical analysis 
 
For statistical analysis of significance, data were analysed using either the unpaired, two-tailed 
students t-test or one-way analysis of variance (ANOVA) as appropriate. Results were 
considered statistically significant at a p value < 0.05 and were calculated using GraphPad 
Prism 6.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Results  
 
3.1 DNA binding affinity and sequence selectivity of diamino Hx-polyamides 2 
and 3 
 
The DNA binding properties of the diamino Hx-polyamides 2 and 3 were investigated to assess 
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the effect of introducing an alkyl amino group at the heterocyclic N1 position. Thermal 
denaturation analysis probed the binding affinity and selectivity of polyamides 2 and 3 by 
measuring their ability to stabilise duplex DNA. The Hx recognition element behaves similarly 
to two consecutive pyrrole units and as a result, polyamides 1, 2 and 3 can degenerately bind 
sequences 5’-ATCGAT-3’ and 5’-TACGAT-3’, with the latter found on the 5’-flank of the ICB2. 
The TM data presented in Table 1 indicate that polyamides 2 (TM = 30C) and 3 (TM = 32C) 
bind to the target sequence (5’-ATCGAT-3’) with greater affinity than their monoamino 
counterpart 1 (TM = 15C), displaying a 2-fold increase in TM relative to HxIP 1 [29]. These 
results show that the additional positively charged alkyl amino group contributes favourably to 
DNA stabilisation. However, polyamides 2 and 3 also showed increased TM values for the 
non-cognate sequences 5’-ACGCGT-3’ and 5’-AAATTT-3’, suggesting an overall decrease in 
sequence selectivity relative to 1, which has previously been shown to have little effect on the 
stabilisation of non-cognate sequences [29]. The increased stabilisation of the oligonucleotides 
by dicationic Hx-polyamides 2 and 3 demonstrated by thermal denaturation is consistent with 
previously published of comparable N1-derivaitized dicationic polyamides [32], [33]. 
 
Circular dichroism (CD) studies confirmed that both diamino Hx-polyamides 2 and 3 bind 
effectively to the 5’-ATCGAT-3’ target sequence in the minor groove (Figure 3A), as shown by 
the emergence of a strong DNA-induced ligand band at ~330 nm. The observation of a clear 
isodichroic point at 305 nm suggests that 2 and 3 bind through a single mechanism, in a 
presumed side-by-side, antiparallel, stacked orientation. However, HxIP* 3 induced a strong 
CD band and clear isodichroic point when titrated to the non-cognate sequences, 
demonstrating that DNA sequence selectivity is reduced by the presence of the second alkyl 
amino group and corroborating the findings from the DNA denaturation experiments.  HxI*P 2 
also bound to the non-cognate sequences, but overlaid CD spectra showed that the CD bands 
were weaker and the isodichroic points less distinct than those observed for 3, confirming the 
overall lower binding affinity of polyamide 2 and highlighting that the position of the N1 
modification affects DNA binding affinity. 
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To further investigate the effect of the N1-alkyl amino group, the binding constants (Keq) of the 
diamino Hx-polyamide 3 were determined using the surface plasmon resonance (SPR) 
biosensor assay. The sensorgrams and steady-state plots shown in Figure 3B/3C, revealed 
that HxIP* 3 binds to the consensus 5’-ATCGAT-3’ site with high affinity (Keq ≈ 3 x 106 M-1 or a 
KD of approximately 0.3 M). Interestingly, diamino Hx-polyamide 3 also binds to the non-
cognate sequence 5’-ATGCAT-3’ (Keq ≈ 2 x 106 M-1) almost as strongly as to the consensus 
sequence, but showed little affinity for 5’-ACGCGT-3’ (Keq < 105 M-1). The favourable binding of 
Hx-polyamide 3 to the non-cognate sequence 5’-ATGCAT-3’ could be due to strong 
electrostatic interactions between the protonated alkyl amino groups and the negatively 
charged phosphodiester backbone of DNA, which could compromise the weaker forces, such 
as hydrogen bonding and hydrophobic interactions, that govern sequence selectivity. 
Alternatively, we cannot rule out the possibility that a stacked, anti-parallel dimer of Hx-
polyamide 3 could interact with 5’-ATCGAT-3’ in a reversed alignment of 3’-to-5’, rather than 
the typical 5’-to-3’ manner. 
 
3.2 Binding of diamino HxI*P and HxIP* on the topo II  promoter 
 
DNase I footprinting studies on the biologically relevant topo II promoter (Figure 4) reveal that 
HxI*P 2 binds to the 5’-TACGAT-3’ target sequence of the 5’-flank of the ICB2 with weaker 
affinity (3 M) than the monoamino HxIP 1 (1 M, [28]) despite showing greater affinity in the 
biophysical studies. HxIP* 3 displayed a 2-fold enhancement of binding affinity relative to 
polyamide 1, generating a footprint evident at 0.5 M, which is in strong agreement with the 
SPR results. Incorporating an additional alkyl amino group had a detrimental effect on the 
sequence selectivity, with both polyamides 2 and 3 showing off-target binding at a sequence 
(5‘-TTGGTT-3’) overlapping the ICB3.  
 
3.3 Disruption of the NF-Y:ICB2 interaction by diamino Hx-polyamides 
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The diamino polyamides inhibit the NF-Y binding to the ICB2 in a cell-free system with 
contrasting effectiveness as shown by electrophoretic mobility shift assay (EMSA) experiments 
(Figure 5). A radiolabelled oligonucleotide containing the ICB2 and target flanking sequence 5’-
TACGAT-3’ was incubated with nuclear protein extract from NIH3T3 cells after pre-treatment 
with HxI*P 2 or HxIP* 3. Supershift studies using an antibody specific for NF-YA confirmed the 
presence of NF-Y within the ICB2-bound protein complex (Figure 5C). HxI*P 2 only affected 
NF-Y binding at higher concentrations of 10-20 M, whereas HxIP* 3 displayed a dose-
dependent inhibition of the NF-Y:ICB2 interaction, evident at doses 3 M. In addition, diamino 
HxIP* 3 was able to displace NF-Y already bound to the ICB2 (Figure 5B), when the 
radiolabelled oligonucleotide was incubated with the nuclear extract prior to the addition of the 
polyamide. The comparative EMSA study of polyamides 2 and 3 emphasises the importance 
of optimising the DNA binding affinity and sequence selectivity to deliver polyamide-directed 
interference of specific protein-DNA interactions.  
 
3.4 Nuclear uptake of diamino Hx-polyamides 
 
Emission studies confirmed that the diamino-containing HxI*P 2 and HxIP* 3 retain the 
characteristic fluorescent output exhibited by Hx-polyamides upon binding DNA and UV 
excitation (322 nm), with emission bands detected at 370 and 375 nm for compounds 2 and 3, 
respectively (data not shown). Previously reported cellular uptake studies of HxIP 1 utilised the 
intrinsic fluorescence of the Hx fluorophore to visualise the rapid polyamide localisation in the 
nucleus [28]. Confocal microscopy and flow cytometry experiments were also used in this study 
to assess the nuclear uptake of polyamides 2 and 3. A549 and NIH3T3 cells were treated with 
increasing concentrations of polyamides for 24 h and representative confocal microscopy 
images are shown in Figure 6. Nuclear uptake of 2 and 3 was confirmed by co-localisation of 
the polyamide fluorescence signal (blue) and propidium iodide (PI) signal (red). HxI*P 2 and 
HxIP* 3 nuclear staining increased in a dose-dependent manner, most prominent after 
exposure to 20 M of each polyamide. Flow cytometry analysis (Figure S2) confirmed the 
confocal microscopy findings, with a 24 h exposure to each diamino polyamide resulting in a 
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concentration-dependent increase in the median fluorescence intensity of the distribution of the 
treated cell populations when compared to the DMSO-treated controls. A 41-fold and 26-fold 
increase was observed after treatment with HxI*P 2 and HxIP* 3, respectively. It is not clear 
whether this difference in fluorescent output is due to the enhanced nuclear uptake of 2 or 
because of lower sequence selectivity, leading to promiscuous nuclear DNA binding and 
therefore greater fluorescence signal. 
To examine polyamide uptake in live, unfixed NIH3T3 cells, the MitoTracker Red dye, which 
stains the mitochondria, was used to define the cytoplasm without cell fixation or 
permeabilisation. The preferential accumulation of the polyamides in the nucleus was observed 
in NIH3T3 cells, with no overlap between the diamino polyamides and the MitoTracker 
fluorescence signals (Figure S3A). A time course experiment revealed the rapid nuclear uptake 
and sustained localisation of both diamino analogues following exposure to 20 M, with blue 
fluorescence signal visible after just 1 h and still evident after 48 h (Figure S3B & C). These 
results highlight the advantage of incorporating the fluorogenic Hx moiety to monitor cellular 
uptake. 
 
3.5 Biological activity of diamino Hx-polyamides in A549 cells 
 
To explore whether the introduction of a second alkyl amino group enhanced polyamide 
biological activity, topo II expression in confluent A549 cancer cells was evaluated by 
measuring topo II mRNA and protein levels after polyamide treatment (Figure 7). HxIP* 3 
induced a dose-dependent increase in topo II mRNA levels as shown by Quantitative RT-
PCR, with expression upregulated by 2.1-fold after 18 h treatment with 2 M polyamide. In 
contrast, HxI*P 2 had no effect on topo II mRNA expression at the same concentration. 
Immunoblot analysis confirmed the differing biological activities of the diamino HxIP analogues. 
Treatment with HxIP* 3 mediated a concentration-dependent (0.1-2 M) enhancement of topo 
II protein levels relative to the untreated cells, with a stimulatory effect exerted at 0.1 M, 
whereas, HxI*P 2 had no effect on the nuclear topo II content (Figure 7B). With both diamino 
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polyamides confirmed to localise in the nucleus via confocal microscopy, these findings indicate 
that the strikingly different in vitro biological activities displayed by 2 and 3 are dictated by the 
position of the additional alkyl amino group and its effect on DNA binding. Importantly, topo II 
expression in A549 cells is upregulated by the dicationic polyamide 3 at a lower concentration 
than reported for the monocationic polyamide 1 [28]. The enhanced polyamide efficacy may be 
a consequence of increased DNA binding affinity and water solubility arising from the inclusion 
of a second positively charged amino group.  
 
3.6 HxIP*- mediated chemosensitisation to topo II poisons 
 
The NF-Y-induced transcriptional downregulation of topo II at confluence results in cellular 
resistance to anti-cancer therapeutics targeting the activity of the enzyme. Previously, we 
reported that the re-induction of topo II expression after treatment with HxIP 1 re-sensitised 
confluent A549 cells to the DNA damaging effects of etoposide, as shown by the increased 
levels of DNA damage marker, H2AX [28]. Here, we show the effects of combining topo II 
poisons with the more biologically active polyamide, HxIP* 3 (Figure 8). Following pre-treatment 
of confluent A549 cells with increasing concentrations of HxIP* for 24 h, cells were exposed to 
50 M etoposide for 2 h and allowed to recover in drug-free medium for a further 24 h before 
visualization of H2AX. Representative immunofluorescence confocal microscopy images 
shown in Figure 8A revealed that HxIP*-etoposide combination treatment regimes initiated a 
polyamide dose-dependent increase in the number of H2AX foci, relative to the etoposide 
treatment alone. The mean number of foci per nuclei was quantified (Figure 8B) using 
CellProfiler Software [36], [37]. Compared to etoposide alone (~0.46 H2AX foci), combination 
treatments with 1 M (~ 1.6 H2AX foci) and 2 M HxIP* (~ 2.5 H2AX foci) induced statistically 
significant 3.5-fold and 5.4-fold increases in H2AX foci, respectively (Figure 8B). HxIP* 
treatment resulted in negligible levels of H2AX as it does not induce DNA damage due to the 
non-covalent binding nature of polyamides. Immunoblot analysis (Figure 8C) corroborated 
these findings and after pre-treatment with HxIP* there was a concentration-dependent 
increase in the phosphorylation of H2AX relative to etoposide alone, with the most significant 
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increase observed after pre-treatment with 5 M HxIP*. A sustained, dose-dependent 
upregulation of nuclear topo II expression by HxIP* was observed in parallel and correlated 
with the enhanced levels of H2AX. 
HxIP* can mediate the chemosensitisation of confluent A549 cells to the cytotoxic effects of 
etoposide and doxorubicin. Cell viability was assessed following single agent HxIP* or 
etoposide treatment, and after HxIP*-etoposide combinations, where 6 h etoposide exposure 
followed 24 h pre-treatment with HxIP*. Combination of etoposide with increasing 
concentrations of HxIP* caused a synergistic dose-dependent decrease in cell viability relative 
to the untreated control. The combination of etoposide (400 M) with 5 μM HxIP* reduced cell 
viability by an additional 50% compared to cells treated with etoposide alone (Figure 8D). HxIP* 
alone had little effect on viability and displayed no cytotoxic effects below 100 μM in exponential 
or confluent A549 cells following 24 h treatment (Figure S4A). Where as, etoposide induced-
cytotoxicity following 6 h exposure was attenuated in confluent-arrested cells (Figure S4B), 
further demonstrating the confluence-mediated resistance to topo II poisons. Finally, polyamide 
induced cellular sensitisation was also observed in combination with doxorubicin (Figure 8E). 
Pre-treatment with 5 μM HxIP* enhanced doxorubicin induced-cytotoxicity causing an additional 
22% decrease in viability relative to cells treated with doxorubicin (75 μM) alone. These results 
confirm the potential application of NF-Y modulating polyamides as chemosensitising agents to 
increase the cytotoxic potency of topo II poisons and reverse the resistance of confluence-
arrested cancer cells. 
 
 
 
 
         
4. Discussion  
 
DNA binding polyamides with programmed sequence recognition are able to chemically control 
transcription and their gene regulatory activities have been confirmed in various biological 
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contexts, targeting a range of transcription factors such as nuclear hormone receptors [6], [8], 
hypoxia-inducible factor 1 (HIF-1) [38], nuclear factor  (NF-) [7] and c-Myc [39]. 
Nevertheless, design strategies that further enhance polyamide activity are still required in order 
to realise the therapeutic potential of this class of small molecules. Recent advances within the 
field have centred on improving the often-modest nuclear uptake properties, which is essential 
for polyamide activity as gene control agents [40], [41], [42], [43]. We reported that the 
incorporation of the p-anisylbenzimidazole (Hx) DNA recognition element into a simple triamide 
structure increases nuclear uptake and the subsequent biological activity of the polyamide HxIP 
1, targeting the repressive DNA binding of transcription factor NF-Y to the ICB2 of the topo II 
promoter [28]. Here, we present the continued evolution of NF-Y targeting polyamides, and 
explore the modification of the Hx-polyamide framework through the introduction of an alkyl 
amino group at the N1 position of either the imidazole (HxI*P 2) or pyrrole (HxIP* 3).  
 
This approach to polyamide functionalization was driven by the higher binding affinity and more 
effective inhibition of transcription factor-DNA interactions by polyamides integrating pyrrole N1-
alkyl spermine/spermidine groups [44], [45]. The results of TM and CD studies confirm that the 
presence of the N1-alkyl amino group increases binding affinity of the diamino Hx-polyamides 
2 and 3 to the cognate sequence, because of electrostatic interactions between the additional 
positively charged amino group and the negatively charged phosphodiester groups of the DNA 
backbone. However, the position of the N1 modification also affected the binding affinity of 
isomers 2 and 3. The inclusion of the propyl amino group at the C-terminal heterocycle of the 
HxIP design (HxIP* 3) caused a greater enhancement of binding affinity than derivatisation of 
the central heterocycle (HxI*P 2). The difference in affinities between the two diamino 
analogues became more apparent following footprinting studies to assess their binding to the 
biologically relevant 5’-TACGAT-3’ sequence on the topo II promoter. Diamino HxIP* 3 
displayed greater binding affinity (0.5 M) than the monoamino HxIP 1 (1 M) [28], whereas 
HxI*P 2 binds to the target sequence with reduced affinity (3 M). The weaker binding affinity 
of polyamide 2 relative to 3 may be due to the closer proximity of the cationic N1-alkyl amino 
groups of the stacked HxI*P 2 dimers when bound in a 2:1 configuration. Electrostatic 
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repulsions between the positively charged groups and steric effects between the alkyl chains 
could cause non-optimal polyamide-DNA binding orientations and compromise DNA binding 
affinity. N1 modification to C-terminal pyrrole on the other hand, limits the electrostatic and 
steric clash as the propyl amino groups of the stacked HxIP* 3 dimers are positioned at the 
maximum possible distance apart.  
 
The importance of the position of the orthogonal propyl amino group in the polyamide design 
was previously revealed when the binding affinities of 5’-ACGCGT-3’ targeting diamino 
triamides were shown to be dependent upon the position of the modified heterocycle, without 
significantly affecting DNA sequence selectivity [30], [31], [32], [33]. In contrast, the diamino 
Hx-polyamides 2 and 3 both display reduced DNA sequence selectivity relative to monoamino 
1, with the integration of the N1-alkyl amino group at the imidazole (HxI*P 2) further 
compromising selectivity compared to attachment to the pyrrole ring (HxIP* 3). This reduced 
selectivity is attributed to the increased positive electrostatic potential of the diamino 
polyamides, due to the presence of a second cationic moiety, resulting in greater attraction to 
the negative potential in the minor groove of AT rich sequences. These findings demonstrate 
how modifications can dramatically influence polyamide-DNA binding characteristics, and 
underlines the importance of functionalities which can enhance DNA binding affinity without 
affecting sequence selectivity to deliver optimised binding properties.  
 
Engineered to derepress the NF-Y-mediated downregulation of topo II, the diamino Hx-
polyamides displayed markedly different in vitro biological activities, seemingly dictated by the 
position of the N1-alkyl amino group and its effect on the polyamide’s ability to disrupt the 
repressive NF-Y:ICB2 interaction. HxI*P 2 had no effect on topo II expression at mRNA or 
protein levels in A549 cancer cells, whereas HxIP* 3 induced upregulation in a dose-dependent 
manner. Previously, polyamides that displayed no biological effect were assumed to be 
incapable of penetrating into the nucleus [27]. Here, confocal microscopy and flow cytometry 
studies exploiting the inherent fluorescence of the diamino Hx-polyamides confirmed the rapid 
and sustained nuclear accumulation of both analogues. Therefore, the inability of HxI*P 2 to 
control topo II transcription can be attributed to the polyamide’s attenuated DNA binding 
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properties and the resulting moderate inhibition of the NF-Y:DNA interaction. In contrast, 
diamino polyamide 3 not only exhibited a greater biological effect than 2, but also stimulated 
upregulation of topo II at  a lower concentration than the monoamino HxIP 1[28]. EMSA 
studies revealed HxIP* 3 and HxIP 1 inhibited the NF-Y:ICB2 interaction with comparable 
efficiency despite footprinting studies showing diamino polyamide 3 to bind to the target 
sequence 5’-TACGAT-3’ with higher affinity [28]. This suggests that the greater induction of 
topo II expression by HxIP* 3 is not solely a result of superior DNA binding. The presence of 
an additional cationic functionality also increases the aqueous solubility of diamino Hx-
polyamides. Taken together, these results indicate that the improved biological effects of 
diamino HxIP* 3 derive from improved physicochemical properties including enhanced water 
solubility arising from the inclusion of a second positively charged alkyl amino group. 
 
The introduction of a N1-alkyl amino group and its position influenced the DNA binding and 
biological activities of diamino Hx-polyamides 2 and 3, and highlights why polyamide 
functionalisation has been widely explored as a strategy to advance their therapeutic potential 
(reviewed in [46]). Dervan and co-workers have reported on the effect of altering the 
composition of the C-terminal tail group of non-fluorescent polyamides [40], [41], [47]. The 
introduction of an isophthalic acid (IPA) group at the C-terminus preserved DNA binding affinity 
and selectivity, and increased potency in cell culture [41]. The attached IPA group enhanced 
nuclear localisation and enabled non-conjugated polyamides to replicate the efficient uptake of 
fluorophore-conjugated derivatives to deliver greater biological effects. An additional 
adjustment to the C-terminus group via the substitution of the amide linkage with an oxime 
linkage between the aliphatic linker and the aromatic tail group further enhanced the potency 
of polyamides targeting the androgen response element [42]. In a different approach, 
Sugiyama’s group tested the introduction of a hydrophilic methoxypolyethylene glycol (PEG) 
750 group as a strategy to address the poor aqueous solubility of their hairpin polyamide seco-
CBI conjugates [48]. Conjugates modified by PEGylation at the hydroxyl group of the seco-CBI 
moiety showed moderately higher solubility and caused greater cytotoxic effects in A549 and 
DU145 cell lines due to improved cell permeability. Furthermore, work in Dervan’s group 
showed that variation of the hairpin polyamide -aminobutyric acid turn (-turn) significantly 
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affected the biological efficacy, pharmacokinetics and toxicity [43], [49], [50]. The integration of 
an aryl group at the -position of the -turn enhanced biological activity against nuclear receptor 
mediated transcription by two orders of magnitude [43]. However, further studies confirmed that 
modifications to the - and -positions of the -turn dramatically altered systemic toxicity of 
polyamides in mice [49], [50]. 
 
The inclusion of a second alkyl amino group did not change the inherently non-cytotoxic 
properties of the Hx-polyamides and no evidence of polyamide-induced DNA damage was 
detected after exposure to diamino polyamide 3. However, when used in combination with 
etoposide and doxorubicin, HxIP* 3 stimulated the chemosensitisation of confluence-arrested 
cancer cells to the DNA damaging effects of these topo II targeting agents. Enhancing cellular 
sensitivity to the cytotoxic effects of topo II poisons through abrogation of the repressive NF-Y 
binding to the ICB2 was first demonstrated using bis-benzimidazole minor groove binder 
Hoechst 33342 [16]. Upregulation of topo II expression in confluent mouse fibroblast NIH3T3 
cells significantly lowered the IC50 value of etoposide in combination treatments and inspired 
the development of sequence specific DNA interacting agents with greater selectivity for the 
critical ICB2 sequence. Hairpin polyamide JH-37 bound to the 5’-TTGGT-3’ sequence 
overlapping the ICB2 and ICB3, and increased formation of DNA strand breaks when NIH3T3 
cells were exposed to polyamide-etoposide treatments, resulting in a synergistic reduction in 
cell viability [25]. Recently, HxIP 1 was the first ICB2-targeting polyamide to sensitise confluent 
cancer cells to etoposide [28]. Here, diamino HxIP* 3, our most potent NF-Y inhibiting 
polyamide to date, re-activated topo II expression and the subsequent increase of etoposide-
generated DNA damage significantly reduced cell viability in combination treatments. The 
enhancement of etoposide and doxorubicin induced-cytotoxicity by diamino Hx-polyamide 3 
reaffirmed the feasibility of direct modulation of transcription factor NF-Y activity as an approach 
to chemosensitisation within the context of cellular confluency. 
 
5. Conclusion 
 
 23 
Polyamide functionalisation via the N1 position of the pyrrole and imidazole rings in the Hx-
framework presents a promising approach to improving the drug-like properties of these small 
molecules. The introduction of an additional cationic alkyl amino functionality enhances water 
solubility and facilitates the nuclear uptake of the diamino polyamides 2 and 3. However, the 
N1-alkyl amino group had a detrimental effect on DNA sequence selectivity, and binding affinity 
for the target sequence 5’-TACGAT-3’ on the topo II promoter was dependent upon the 
position of the modified heterocycle. The diamino polyamides displayed strikingly different in 
vitro biological activities. HxI*P 2 showed no effect against the downregulation of topo II at 
confluence, while HxIP* 3 stimulated a dose-dependent upregulation of topo II expression. 
This discrepancy is seemingly dictated by their contrasting abilities to disrupt the NF-Y:ICB2  
interface. Overall, the correct positioning of a second alkyl amino group in the HxIP structure 
generated a more potent dicationic polyamide, benefiting from superior solubility relative to its 
monocationic counterpart. Targeted inhibition of NF-Y binding by HxIP* 3 and the subsequent 
re-induction of topo II levels potentiated the cytotoxicity of topo II poisons. These results further 
highlight the need for in vivo investigation of the efficacy of drug combination strategies that 
employ polyamides to overcome resistance to clinically-used anticancer therapeutics.  
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Figure Legends 
 
Figure 1: Schematic representation of the confluence-induced downregulation of topo II, 
mediated by the repressive binding of NF-Y to the ICB2. The ICB sequence ATTGG is 
highlighted in blue and the 5’-flanking sequence of the ICB2 is outlined with a dashed box. 
 
Figure 2: Design of the diamino Hx-polyamides 2 and 3. (A) Structures of the monoamino Hx-
polyamide, HxIP 1 and the orthogonally positioned diamino-containing derivatives, HxI*P 2 and 
HxIP* 3. The asterisk (*) denotes position of the N-alkyl amino group. (B) Schematic models of 
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polyamides 2 and 3 binding to the 5’-TACGAT-3’ sequence on the 5’-flank of the ICB2 in an 
antiparallel 2:1 fashion as an overlapped stacked dimer. 
 
Table 1: Thermal denaturation values and SPR equilibrium binding constants for polyamides 
HxIP 1, HxI*P 2 and HxIP* 3.   
 
Figure 3: Biophysical comparison of the diamino Hx-polyamide DNA binding characteristics. 
(A) CD spectra for HxIP* 3 (top panel) and HxI*P 2 (bottom) binding with the target sequence 
5’-ATCGAT-3’ and non-consensus sequences 5’-AAATTT’-3 and 5’-ACGCGT-3’. (B) SPR 
sensorgram of HxIP* 3 with the target 5’-ATCGAT-3’ sequence at 100, 200 and 300 nM 
concentrations of compound. Thick grey lines represent true association and dissociation and 
thin black lines represent global kinetics fits. (C) Steady-state analyses of HxIP* 3 with 5’-
ATGCAT-3’ (, solid line), 5’-ATCGAT-3’ (, dashed line), and 5’-ACGCGT-3’ (, dotted line) 
sequences. SPR experiments were run in 10 mM CCL, 1 mM EDTA, 200 mM NaCl, 0.05% P20 
(pH 6.5) at 25 °C. 
 
Figure 4: Binding of diamino Hx-polyamides 2 and 3 to the topo II promoter. Autoradiograms 
of DNase I footprinting gels, HxI*P 2 (left) and HxIP* 3 (right). The concentrations (M) used 
are shown at the top of the gel. G+A represents a formic acid-piperidine marker specific for 
purines. The positions of the ICB1, ICB2, ICB3 and the target sequence are indicated. 
 
Figure 5: Inhibition of NF-Y binding to ICB2 by the diamino Hx-polyamides. Electrophoretic 
mobility shift assays (EMSAs) using a radiolabelled oligonucleotide containing the ICB2 and 
target sequence 5’-TACGAT-3’ were pre-incubated with increasing concentrations of polyamide 
2 or 3 for 1 h at room temperature prior to addition of the NIH3T3 nuclear extract. 0, control 
reaction containing the oligonucleotide and nuclear extract without polyamide; C, reaction in 
the presence of an excess of unlabelled competitor oligonucleotide of the same sequence as 
the control reaction; M, reaction in the presence of an excess of unlabelled oligonucleotide with 
a mutation to the ICB2 motif. (A) Comparative analysis of the inhibitory effects of HxI*P 2 and 
HxIP* 3 on the binding of NF-Y containing protein complexes to the ICB2. (B) EMSA showing 
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HxIP* 3 is able to displace NF-Y already bound to the ICB2 when the radiolabelled 
oligonucleotide is pre-incubated with the nuclear extract prior to the addition of the polyamide. 
(C) Supershift analysis using an anti-NF-YA antibody confirmed the presence of NF-Y in the 
protein complex bound to the radiolabelled oligonucleotide. 
 
Figure 6: Visualisation of HxI*P 2 and HxIP* 3 nuclear localisation. A549 (top panels) and 
NIH3T3 (bottom panels) cells were treated with the indicated concentrations of HxI*P (left) or 
HxIP* (right) for 24 h, washed with PBS, and fixed with 2% paraformaldehyde (PFA). They were 
subsequently permeabilised and the nuclei were stained with propidium iodide (PI) before 
confocal microscopy imaging. The composite image presents the superimposed overlay of 
diamino Hx-polyamide fluorescence and the PI fluorescence. No polyamide fluorescent signal 
was detected in the control, untreated cells under the same observation settings. 
 
Figure 7: Effect of the diamino HxIP derivatives on topo II expression in confluent A549 cells. 
(A) Quantification of topo II mRNA levels via RT-PCR analysis. Cells were maintained at 
confluency before 18 h treatment with increasing concentrations of HxI*P 2 or HxIP* 3.  mRNA 
levels are compared relative to untreated confluent A549 cells (CON). Error bars represent the 
SEM from three biological replicates. Statistical significance was calculated using one-way 
ANOVA analysis (* p < 0.05). (B) Immunoblot analysis of confluent A549 nuclear extracts 
probed with topo II antibody following 18 h treatment with HxI*P 2 or HxIP* 3. Lamin is shown 
as a loading control. 
 
 
Figure 8: Potentiation of topo II poison induced-cytotoxicity by HxIP*. A549 cells were pre-
treated with the indicated concentrations of HxIP* 3 for 24 h and exposed to etoposide (50 M) 
for 2 h. After 24 h in drug free medium, they were analysed for H2AX levels by confocal 
microscopy and immunoblotting. (A) Representative images of A549 cells. (B) Number of H2AX 
foci per nuclei for the indicated treatment combinations, as quantified by CellProfiler Software. 
(C) Immunoblot analysis of the nuclear levels of H2AX and topo II, 24 h after pre-treatment 
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with HxIP* for 24 h, treatment with etoposide for 2 h and their combination. (D) Confluent A549 
cells were treated with HxIP* (2 and 5 M) or etoposide (400 M) and HxIP*-etoposide 
combination, where 6 h etoposide exposure followed 24 h pre-treatment with HxIP*. Cell 
viability (%) was measured using the CellTiter-Glo assay. Luminescence values are 
normalised to those of the untreated control. (E) Viability was also assessed after 6 h treatment 
with doxorubicin (75 M) and HxIP*-doxorubicin combinations, where 6 h exposure followed 24 
h HxIP* pre-treatment. All data are represented as mean ± SEM (n=3). Statistical significance 
was calculated using one-way ANOVA analysis (* p < 0.05, ** p < 0.01, *** p < 0.001). 
 
 
